Kathryn H Williams1, Kharis Burns2, Maria Constantino3, Nicholas A Shackel4, Emilia Prakoso5, Jencia Wong6, Ted Wu7, Jacob George8, Geoffrey W McCaughan9, Stephen M Twigg10. 1. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050; Charles Perkins Centre and Bosch Institute, Building D17, The University of Sydney, New South Wales, Australia, 2006. Electronic address: kath.williams@sydney.edu.au. 2. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Westmead Hospital, Cnr Darcy Road and Bridge Street, Westmead, NSW, Australia, 2145. Electronic address: kbur9770@uni.sydney.edu.au. 3. Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050. Electronic address: Maria.Constantino@sswahs.nsw.gov.au. 4. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050; Centenary Institute, Locked Bag 9, Newtown, New South Wales, Australia, 2042. Electronic address: n.shackel@centenary.usyd.edu.au. 5. Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050; Centenary Institute, Locked Bag 9, Newtown, New South Wales, Australia, 2042. Electronic address: e.prakoso@centenary.org.au. 6. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050. Electronic address: jencia.wong@sswahs.nsw.gov.au. 7. Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050. Electronic address: Ted.Wu@sswahs.nsw.gov.au. 8. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Westmead Hospital, Cnr Darcy Road and Bridge Street, Westmead, NSW, Australia, 2145; Westmead Millennium Institute for Clinical Research, P.O. Box 412, Westmead, New South Wales, Australia, 2145. Electronic address: jacob.george@sydney.edu.au. 9. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050; Centenary Institute, Locked Bag 9, Newtown, New South Wales, Australia, 2042. Electronic address: g.mccaughan@centenary.org.au. 10. Central Clinical School, Room 408, Blackburn Building D06, The University of Sydney, New South Wales, Australia, 2006; Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia, 2050; Charles Perkins Centre and Bosch Institute, Building D17, The University of Sydney, New South Wales, Australia, 2006. Electronic address: stephen.twigg@sydney.edu.au.
Abstract
AIM: To examine for an association of elevated lower-limb vibration perception threshold (VPT) with NAFLD fibrosis. METHODS: Two cohorts from a tertiary diabetes centre were studied - Cohort 1, n=456 with type 1 or 2 diabetes, and Cohort 2, n=106 with type 2 diabetes mellitus. All underwent a detailed assessment, including VPT measurement. Cohort 2 also had liver ultrasound and transient elastography (TE). NAFLD Fibrosis Score (NFS) was calculated for all with available data. Follow-up VPT measurements on participants in Cohort 1 to 2014 were also collected if available. RESULTS: Adjusted risk of higher VPT category (≥25V but <50V, or ≥50V, c.f. < 25V) was greater for high-risk NFS in both cohorts (Cohort 1, OR 2.22 [95% CI 1.24-3.98, p=0.007] and Cohort 2, OR 4.51 [95% CI 1.08-18.87], p=0.039) and higher liver stiffness measurement (LSM) by TE in Cohort 2 (OR for each unit natural log increase in LSM of 2.42 (95% CI 1.13-5.19), p=0.023). In Cohort 1, in those with VPT<50V and complete data, those with higher NFS had greater odds of increasing VPT category after 2.2 (IQR 1.5-2.9) years. CONCLUSIONS: Higher VPT associates with markers of liver fibrosis due to NAFLD in diabetes mellitus.
AIM: To examine for an association of elevated lower-limb vibration perception threshold (VPT) with NAFLD fibrosis. METHODS: Two cohorts from a tertiary diabetes centre were studied - Cohort 1, n=456 with type 1 or 2 diabetes, and Cohort 2, n=106 with type 2 diabetes mellitus. All underwent a detailed assessment, including VPT measurement. Cohort 2 also had liver ultrasound and transient elastography (TE). NAFLD Fibrosis Score (NFS) was calculated for all with available data. Follow-up VPT measurements on participants in Cohort 1 to 2014 were also collected if available. RESULTS: Adjusted risk of higher VPT category (≥25V but <50V, or ≥50V, c.f. < 25V) was greater for high-risk NFS in both cohorts (Cohort 1, OR 2.22 [95% CI 1.24-3.98, p=0.007] and Cohort 2, OR 4.51 [95% CI 1.08-18.87], p=0.039) and higher liver stiffness measurement (LSM) by TE in Cohort 2 (OR for each unit natural log increase in LSM of 2.42 (95% CI 1.13-5.19), p=0.023). In Cohort 1, in those with VPT<50V and complete data, those with higher NFS had greater odds of increasing VPT category after 2.2 (IQR 1.5-2.9) years. CONCLUSIONS: Higher VPT associates with markers of liver fibrosis due to NAFLD in diabetes mellitus.
Authors: Geraldine F Clough; Andrew J Chipperfield; Marjola Thanaj; Eleonora Scorletti; Philip C Calder; Christopher D Byrne Journal: Front Physiol Date: 2020-06-03 Impact factor: 4.566
Authors: Lawrence J Coppey; Hanna Shevalye; Alexander Obrosov; Eric P Davidson; Mark A Yorek Journal: J Diabetes Investig Date: 2018-03-25 Impact factor: 4.232